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Abstract Methods for the preparation of symmetrical and non-symmetrical 
2,7-disubstituted 9H-fluorene derivatives are described. 
Key words  Fluorene, sulfonamide, microwave assisted synthesis 
 
Fluorene (1) represents a privileged structure that has found a 
wide variety of applications in synthetic, medicinal and 
materials chemistry. The defined shape and electronics of 1 
impart important functional properties on derivatives.1 For 
example, C2 symmetric bis-sulfonamide 2 is an effective ligand 
in the rhodium catalysed asymmetric transfer hydrogenation of 
ketones.2 Bis-sulfonamides are also prevalent in many 
commercial screening libraries and have been identified as hit 
compounds on diverse protein targets including alanine 
racemase,3 cysteine protease,4 and 17E-HSD1.5 In addition, bis-
sulfonamide 3 has been used in chemical biology as a novel DNA 
G quadruplex ligand showing further applications for this class 
of compound.6 For each of these examples the rigid scaffold of 
fluorene provides the requisite geometry for function, holding 
substituents in a specific position. Along with the structural 
properties imparted by the framework, the conjugated nature of 
the two aromatic rings and the acidic methylene protons dictate 
the properties of derivatives. For example, bis-sulfonylated 
fluorenes have found use in areas such as self-assembled 
monolayer arrays for molecular electronic devices,7 compounds 
with room temperature phosphorescent emission properties,8 
charge transfer complexes,9 and merocyanine dyes.10 Therefore, 
new methods for the preparation of fluorene derivatives that 
allow access to alternative and more complex scaffolds will be of 
interest to the synthetic community. 
 
Figure 1 Fluorene 1 and symmetrical bis- sulfonamide derivatives. 
A key feature of fluorene chemistry that directs many of the 
applications of this framework is the regiospecific electrophilic 
aromatic sulfonylation,7a nitration11 and halogenation,12 which 
leads to 2,7-disubstituted systems for further elaboration. 
Surprisingly, the majority of fluorene derivatives reported to 
have function within the literature are symmetrical derivatives, 
presumably due to their ease of synthesis, and we were unable 
to identify effective methods to prepare non-symmetrical 
compounds despite the potential applications of these products. 
Within this paper we describe simple and effective methods for 
the preparation of mono-sulfonamides together with 
symmetrical and non-symmetrical bis-sulfonamides from 
commercial fluorene building blocks and also provide 
preliminary data to show a method for the preparation of 
aniline and amide substituted fluorene mono-sulfonamides. 
As part of our ongoing investigations in nuclear receptor 
chemistry,13 virtual screening identified the symmetrical bis-
sulfonamide 9 as a potential hit compound which was therefore 
physically required for biological evaluation. Bis-sulfonyl 
chloride 4 was prepared by a modified literature procedure7a 
and isolated without the need for purification by 
chromatography (see the Supporting Information for full 
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Scheme 1 Preparation of non-symmetrical fluorene derived bis-sulfonamides. 
details). To our surprise, an experimental procedure for the 
mono- sulfonylation of fluorene has not been detailed in the 
literature.14 Application of standard reaction conditions with 
careful control of stoichiometry led to the selective sulfonylation 
of fluorene, and subsequent chlorination gave mono-sulfonyl 
chloride 6 in 75% yield over two steps. 
Thermal methods have been described for the preparation of 
sulfonamides from the corresponding sulfonyl chloride. Whilst 
these methods proved effective, an alternative microwave 
procedure was established which proved more convenient due 
to the short reaction times involved (typically <15 minutes). 
(Table 1). 
 
Entry Reactant R
1 
R
2 
Product Yield
a 
1 4 H Ph 8 93 
2 4 H 4-MeC6H4 9 54 
3
b 
4 H 4-HOC6H4  34 
4 4 Me 4-MeC6H4  85 
5 4 H Cy  60 
6 4 H 
i
Pr  71 
7 4 H 4-THP  55 
8 6 H 
i
Pr  77 
9 6 H 4-MeC6H4  62 
10 6 -CH2(CH2)2CH2-  83 
a
Isolated yield after purification by column chromatography. 
b
Reaction heated for 1 h. 
Table 1 Preparation of fluorene derived sulfonamides. 
Heating bis-sulfonyl chloride 4 in the presence of 2 equivalents 
of aniline in a mixture of THF, NaOH (2 M) and acetone at 100 °C 
for 15 minutes provided the bis-sulfonamide 8 (Entry 1, 93%) 
after purification by column chromatography. This method 
proved effective for both primary (Entries 1Ȃ3) and secondary 
(Entry 4) anilines. Aliphatic amines were also shown to be 
efficient substrates for the transformation (Entries 5Ȃ7) and 
suggest this should be an effective and general method for the 
preparation of this class of compound. Reaction of mono-
sulfonyl chloride 6 with 1 equivalent of amine gave the 
corresponding mono-sulfonamides in good yields. The reaction 
was found to be tolerant of primary and secondary amines along 
with aniline substrates (Entries 8Ȃ10). 
Having prepared a series of symmetrical bis- and mono-
sulfonamides we were eager to discover if we could also access 
non-symmetrical derivatives. Attempts were made to use mono-
sulfonamides 7 as precursors to non-symmetrical bis-
sulfonamides, however, standard sulfonylation conditions 
(HSO3Cl, AcOH, 140 °C) proved incompatible with the existing 
sulfonamide functionality, leading to intractable mixtures of 
products. 
Recent work has shown that aryl sulfonamides can be accessed 
in a two-step one-pot procedure through a palladium catalysed 
sulfination followed by reaction of the aryl sulfinate 
intermediate with an amine in the presence of 
N-bromosuccinimide (NBS).15 With this in mind, we envisaged 
non-symmetrical bis-sulfonamides could be accessed by the 
route outlined in Scheme 1. 
Conversion of 2-bromofluorene 18 to the sulfonyl chloride 19 
proceeded smoothly under standard reaction conditions (80%, 
two steps), which was treated with p-toluidine (1 eq.) to give the 
corresponding sulfonamide 20 (63%). Reaction of this substrate 
with morpholine under the conditions described by Shavnya et 
al.15 gave the corresponding sulfonamide 21 in 77% yield. 
Unfortunately, complex mixtures of products were observed 
when performing this protocol using aniline or primary amine 
starting materials. The fluorene scaffold can readily undergo 
both oxidation and deprotonation which we believe to be the 
origin of the multiple products observed when using alternative 
amines within this protocol. 
We also examined alternative palladium catalysed coupling 
processes for the introduction of additional functional groups of 
relevance to catalysis, medicinal chemistry and materials 
chemistry (Scheme 2). Treatment of bromo sulfonamide 20 with 
morpholine in the presence of RuPhosPd under microwave 
irradiation at 120 °C for 30 minutes provided the Buchwald-
Hartwig coupling product 22 in 72% isolated yield after 
purification by column chromatography.16 We were also able to 
directly access amide derivatives of 20 by microwave 
irradiation at 90 °C for 30 minutes in the presence of 
morpholine, Pd(OAc)2, xantphos as a supporting ligand, Mo(CO)6 
  
and DMAP, providing 23 in 76% isolated yield.17 These initial 
examples suggest that 20 should be an effective substrate for a 
variety of palladium catalysed coupling procedures, further 
adding to the potential diversity and subsequent application of 
the products. 
 
Scheme 2 Palladium catalysed synthesis of non-symmetrical fluorene 
derivatives. 
It is established that aryl iodides can be beneficial in palladium 
catalysed transformations due to an increased rate of oxidative 
addition. We envisaged that the scope of the sulfonamide 
forming reaction could be improved through the use of aryl 
iodide substrate 24 (Scheme 3). Sulfonyl chloride 25 was 
prepared using standard conditions in an excellent yield over 
two steps (88%), without the need for chromatographic 
purification. The intermediate sulfonyl chloride 25 was 
sensitive to heating in the presence of a base, but a modified 
procedure employing 2 equivalents of amine and stirring at 
room temperature overnight overcame this problem, giving 
sulfonamides 26 and 27 in good yields (See Supporting 
Information for full details). 
 
Scheme 3 Preparation of iodo sulfonamides. 
Sulfonamide 26 was reacted with morpholine under the 
conditions described by Shavnya et al.,15 however, a complex 
mixture of products was observed by LCMS. A modest yield 
(48%) of 21 was achieved by using 5 equivalents of K2S2O5, 
however, despite extensive exploration of reaction conditions, a 
number of unidentified products predominated when using 
primary amines or anilines in this reaction. Alternative reported 
methods for the preparation of aryl sulfonamides from aryl 
halides were applied to sulfonamides 26 and 27, however, in 
each case multiple products were observed.18 
A non-elegant, transition-metal free solution to the preparation 
of non-symmetrical bis-sulfonamides was found by treating bis-
sulfonyl chloride 4 with one equivalent of p-toluidine under 
basic reaction conditions, giving sulfonamide 28 in 15% yield 
after purification by column chromatography (Scheme 4). 
Subsequent reaction with oxalyl chloride gave sulfonyl chloride 
29 which was then reacted with ethanolamine or 3-
hydroxypropylamine to give the non-symmetrical bis-
sulfonamides 30 (95%) and 31 (43%) respectively. Of the 
methods examined this provided the most convenient process 
to access arrays of non-symmetrical bis-sulfonamide targets in a 
reliable, time efficient and cost effective manner. 
 
Scheme 4 Preparation of non-symmetrical fluorene derived bis-sulfonamides. 
In summary, we have described methods for the preparation of 
symmetrical and non-symmetrical fluorene sulfonamide 
derivatives. Mono- and symmetrical bis-sulfonamides can be 
readily accessed through the microwave irradiation of the 
corresponding sulfonyl chloride in the presence of an amine, 
allowing access to the products in short reaction times. Non-
symmetrical bis-sulfonamides can be prepared in lower yields 
through the mono-functionalisation of bis-sulfonyl chloride 4, 
followed by purification, reaction with oxalyl chloride and then 
treatment with a second amine. Application of a palladium 
catalysed sulfonylation process also provides access to selected 
non-symmetrical bis-sulfonamides but this transformation 
proved dependent on the structure of the amine nucleophile. 
Aniline and amide derivatives of the fluorene scaffold can also 
be prepared using transition-metal catalysed coupling 
processes, adding to the structural diversity accessible through 
this methodology. Given the significant number of applications 
known for symmetrical fluorene derivatives in diverse areas 
including asymmetric catalysis, medicinal chemistry and 
materials science it is expected that this work will provide the 
impetus for further discovery in the application of the fluorene 
skeleton. 
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References and Notes 
General procedure for the microwave assisted formation of 
sulfonamides: 
9H-Fluorene-2,7-disulfonyl dichloride 4 (100 mg, 0.28 mmol), 
acetone (1.52 mL), THF (0.28 mL), amine (0.56 mmol) and 2M 
NaOH (aq) (0.32 mL) were added to a 5 mL microwave vial 
equipped with a magnetic stirrer bar. The mixture was heated in 
a Biotage Initiator at 100 °C for 15 min, and allowed to cool to 
room temperature. Dichloromethane (10 mL) was added, and the 
mixture washed with water (10 mL), saturated sodium carbonate 
solution (10 mL), 2M HCl (aq) solution (10 mL) and brine (10 
mL). The organic extract was dried over magnesium sulfate, 
filtered and concentrated under reduced pressure to give the 
crude product. 
N,N-Diisopropyl-9H-fluorene-2,7-disulfonamide 13. Prepared 
by the General Procedure, using isopropylamine (0.05 mL, 0.58 
mmol). Purified by column chromatography on silica (2:1 
petroleum ether: ethyl acetate, followed by 1:1) to give 13 as a 
yellow-ȋ ? ?ǡ ? ? ?ȌǢǤǤ ? ? ?ԟ ? ? ? ?ǢIR (ATR/cm-
1): 3054, 2990, 1456, 1403, 1304, 1235, 1181, 1103; 1H (400 MHz, 
DMSO d6ȌɁ ?Ǥ ? ?ȋ ?ǡǡJ = 8.1 Hz), 8.06 (2H, d, J = 0.8 Hz), 7.89 
(2H, dd, J = 8.1, 1.5 Hz), 7.61 (2H, d, J = 7.2 Hz), 4.18 (2H, s), 3.22Ȃ
3.35 (2H, m), 0.96 (12H, d, J = 6.5 Hz); 13C (101 MHz, DMSO d6ȌɁ
144.7 (quat C), 143.0 (quat C), 141.1 (quat C), 125.5 (CH), 123.4 
(CH), 121.5 (CH), 45.2 (CH), 36.7 (CH2), 23.2 (CH3); LCMS m/z = 
407.1 (M-1)+; HRMS calc. for C19H23O4N2S2 407.1105, found 
407.1107. 
Palladium catalysed procedures: 
7-(Morpholinosulfonyl)-N-(p-tolyl)-9H-fluorene-2-
sulfonamide 21. A microwave vial was charged with 20 (30.0 
mg, 0.062 mmol), potassium metabisulfite (33.0 mg, 0.148 mmol), 
tetra-n-butylammonium bromide (26.3 mg, 0.082 mmol), sodium 
formate (12.0 mg, 0.176 mmol), palladium acetate (1.0 mg, 5 mol 
%), triphenylphosphine (3.0 mg, 0.013 mmol), 1,10-
phenanthroline (2.0 mg, 0.011 mmol) and DMSO (0.2 mL). The 
mixture was degassed by bubbling nitrogen through the solvent 
for 10 minutes, and then heated under argon at 70 °C for 3 hours. 
Following cooling to room temperature, a solution of morpholine 
(12.6 mg, 0.145 mmol) in anhydrous THF (1.0 mL) was added and 
the mixture cooled to 0 °C. A solution of N-bromosuccinimide 
(25.8 mg, 0.145 mmol) in THF (1.0 mL) was added drop-wise and 
the mixture left to warm to room temperature over one hour. 
Water (10 mL) was added, and the mixture extracted with ethyl 
acetate (3 × 10 mL). The organics were combined and washed 
with water (20 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to give the crude product, 
which was purified by column chromatography (1:1 petroleum 
ether: ethyl acetate) to give 21 as a yellow solid (27 mg, 77%); 1H 
NMR (400 MHz, Acetone d6ȌɁ ?Ǥ ? ?ȋ ?ǡȌǡ ?Ǥ ? ?ȋ ?ǡǡJ = 8.0 Hz), 
8.11 (1H, d, J = 8.4 Hz), 8.01Ȃ8.06 (2H, m), 7.81Ȃ7.88 (2H, m), 7.11 
(2H, d, J = 8.4 Hz), 7.04 (2H, d, J = 8.4 Hz), 4.14 (2H, s), 3.62Ȃ3.72 
(4H, m), 2.93Ȃ3.03 (4H, m), 2.21 (3H, s); 13C NMR (101 MHz, 
Acetone d6ȌɁ ? ? ?Ǥ ?ȋȌǡ ? ? ?Ǥ ?ȋȌǡ ? ? ?Ǥ ?ȋȌǡ ? ? ?Ǥ ?
(quat C), 140.5 (quat C), 136.1 (quat C), 135.7 (quat C), 135.3 
(quat C), 130.5 (CH), 128.0 (CH), 127.3 (CH), 125.8 (CH), 125.1 
(CH), 122.5 (CH), 122.3 (CH), 122.2 (CH), 66.7 (CH2), 47.1 (CH2), 
37.7 (CH2), 20.7 (CH3); LCMS m/z = 483.2 (M-1)+; HRMS m/z: 
calcd. for C25H25N2O5S2 485.1199, found 485.1189. 
7-Morpholino-N-(p-tolyl)-9H-fluorene-2-sulfonamide 22. A 
mixture of RuPhos Palladacycle (7 mg, 0.05 equiv.), RuPhos (5 
mg, 0.05 equiv.), sodium tert-butoxide (29 mg, 0.30 mmol), 7-
bromo-N-(p-tolyl)-9H-fluorene-2-sulfonamide (83 mg, 0.20 
mmol) and morpholine (0.021 mL, 0.24 mmol) in 1,4-dioxane 
(0.50 mL) was sealed and heated in a Biotage Initiator at 120 °C 
for 30 min. After cooling, the sample was passed through a plug of 
celite using MeOH (10.0 mL), then concentrated under reduced 
pressure to give the crude product, which was purified by column 
chromatography (1:1 petroleum ether: ethyl acetate) to give 21 
(59 mg, 72%) as a yellow solid; m.p. 170 °C (decomp.); IR 
(ATR/cm-1): 2922, 1612, 1512, 1451, 1419, 1243, 1189, 1111; 1H 
(400 MHz, CDCl3ȌɁ ?Ǥ ? ?ȋ ?ǡǡJ = 1.2 Hz), 7.70 (1H, dd, J = 8.0, 
0.8 Hz), 7.67 (1H, d, J = 8.8 Hz), 7.64 (1H, d, J = 8.4 Hz), 7.10 (1H, d, 
J = 2.0 Hz), 6.99Ȃ7.04 (2H, m), 6.92Ȃ6.98 (3H, m), 6.41 (1H, s), 
3.86Ȃ3.92 (4H, m), 3.83 (2H, s), 3.20Ȃ3.28 (4H, m), 2.26 (3H, s); 
13C (101 MHz, CDCl3ȌɁ ? ? ?Ǥ ?ȋȌǡ ? ? ?Ǥ ?ȋȌǡ ? ? ?Ǥ ?ȋ
C), 143.1 (quat C), 135.6 (quat C), 135.4 (quat C), 134.0 (quat C), 
133.3 (quat C), 130.0 (CH), 126.7 (CH), 123.8 (CH), 122.7 (CH), 
121.8 (CH), 118.9 (CH), 115.2 (CH), 112.1 (CH), 67.0 (CH2), 49.5 
(CH2), 37.1 (CH2), 21.0 (CH3); LCMS m/z = 421.1 (M+1)+; HRMS 
m/z: calcd. for C24H25N2O3S 422.1580, found 422.1577. 
7-(Morpholine-4-carbonyl)-N-(p-tolyl)-9H-fluorene-2-
sulfonamide 23. A mixture of palladium acetate (2.0 mg, 0.05 
eq.), Xantphos (6.0 mg, 0.05 eq.), Molybdenum hexacarbonyl 
(53.0 mg, 0.05 equiv.), DMAP (37.0 mg, 0.30 mmol), 7-bromo-N-
(p-tolyl)-9H-fluorene-2-sulfonamide (83.0 mg, 0.20 mmol) and 
morpholine (0.034 mL, 0.39 mmol) in 1,4-dioxane (0.50 ml) was 
sealed and heated in a Biotage Initiator at 90 °C for 30 min. After 
cooling, the reaction mixture was passed through celite using 
MeOH (10.0 mL), then concentrated under reduced pressure to 
give the crude product, which was purified by column 
chromatography (4:1 petroleum ether: ethyl acetate) to give 22 
as a yellow solid (0.068 g, 76%); m.p. 210 °C (decomp.); IR 
(ATR/cm-1): 2925, 2853, 1619, 1605, 1445, 1332, 1243, 1191, 
1148, 1111, 1049; 1H NMR (400 MHz, CDCl3ȌɁ ?Ǥ ? ?ȋ ?ǡǡJ = 0.7 
Hz), 7.82 (1H, d, J = 8.0 Hz), 7.75Ȃ7.80 (2H, m), 7.62 (1H, d, J = 0.8 
Hz), 7.45 (1H, dd, J = 8.0, 1.2 Hz, 1H), 7.02 (2H, d, J = 8.0 Hz), 6.96 
(2H, d, J = 8.0 Hz), 6.77 (1H, br s), 3.91 (2H, s), 3.50 Ȃ 3.87 (8H, m), 
2.25 (3H, s); 13C NMR (101 MHz, CDCl3Ȍ Ɂ  ? ? ?Ǥ ? ȋ Ȍǡ  ? ? ?Ǥ ?
(quat C), 144.6 (quat C), 144.1 (quat C), 141.6 (quat C), 137.9 
(quat C), 135.7 (quat C), 135.2 (quat C), 133.8 (quat C), 130.0 
(CH), 126.7 (CH), 126.4 (CH), 124.4 (CH), 124.2 (CH), 122.7 (CH), 
121.0 (CH), 120.6 (CH), 67.0 (CH2), 37.1 (CH2), 21.0 (CH3), 1 
carbon missing; LCMS m/z = 449.1 (M+1)+; HRMS m/z: calcd. for 
C25H25N2O4S 449.1530, found 449.1530. 
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